Target CEO: Expect swift price increases on certain items due to Trump tariffs
That was higher than the 0.3% gain during the third quarter. Target posted a 2% gain in the second quarter and a 3.7% drop in ...
Target’s stock gains as earnings outlook doesn’t disappoint, unlike rivals
Target’s profit will be pressured in the first quarter due to tariff uncertainty and bad weather, but will then see ...
Trump tariffs give struggling Target cover to make one big change, at the expense of investors
The company also cut its long-term outlook at its New York City investor day, much to the frustration of analysts. Target ...
Another Wall Street Bull Cuts S&P 500 Target. It Misread Trump on Tariffs.
Investors have rapidly been losing faith in the stock market—one of Wall Street’s most prominent bulls just joined their ...
Business Insider10d
Gain Therapeutics initiated with an Outperform at Scotiabank
Scotiabank initiated coverage of Gain Therapeutics (GANX) with an Outperform rating and $12 price target Gain’s GT-02287 is potential blockbuster drug in Phase 1b that could be a disease-modifyi ...
Target Unveils $15 Billion Sales Growth Strategy With Focus on Digital Expansion
Target plans to drive $15B in sales growth by 2030 by expanding product categories, digital marketplace, owned brands, stores ...
Yahoo Finance7d
Target stock tanks as it issues rough first quarter profit warning due to Trump tariffs
Target (TGT) may have to do a lot more this year ... 1.18% estimate (Last year comparable sales fell 4.4%; Walmart US reported a 4.6% gain in its fourth quarter.) ...
ETF Daily News5d
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus Price Target from Brokerages
Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 target price on shares of Gain ...